HILL DERMAC
SpecialtyHILL DERMAC is a specialty pharmaceutical company focused on Immunology, Dermatology.
HILL DERMAC's Key Drugs
HILL DERMAC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HILL DERMAC's Recent FDA Approvals
New NDA/BLA approvals for HILL DERMAC over the last two years — novel drugs only, excluding generics and label supplements.
HILL DERMAC's Therapeutic Areas
HILL DERMAC's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HILL DERMAC's Top Competitors
HILL DERMAC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HILL DERMAC Pipeline Snapshot
HILL DERMAC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1988-02-03
- Latest
- 2024-08-30
- Applications
- 1